Compare Heron Therapeutics Inc (HRTX) vs Manulife Financial Corporation (MFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Manulife Financial Corporation — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $74.04M), while Manulife Financial Corporation trades at $43.58 (market cap $69.26B). The key difference: Manulife Financial Corporation is far larger — about 935.4× Heron Therapeutics Inc's market cap, and Manulife Financial Corporation pays a 3.27% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Manulife Financial Corporation for 119 Days on average.
| HRTX | MFC | |
|---|---|---|
Market Cap | $74.04M | $69.26B |
Volume | 3,668,095 | 1,347,387 |
Sector | Health | Financials |
52-Week High | $1.49 | $44.77 |
52-Week Low | $0.27 | $31.64 |
Typical Hold Time | 35 Days | 119 Days |
Enterprise Value | $180.78M | $64.51B |
Dividend Yield | — | 3.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
Manulife Financial (MFC) trades at $41.67, down 2.94% with bearish technical signals despite strong fundamentals. The company reported solid Q2 2026 earnings of $0.79 per share, beating expectations, with revenue growth to $53.01 billion in 2025 and improving cash flow trends. Recent institutional investments from Bank of America and executive appointments signal confidence in long-term strategy.
MFC presents a mixed outlook with strong profitability metrics (11.7% net margin, 13.88% ROE) and analyst consensus favoring Buy ratings (57%), but faces technical headwinds and premium valuation concerns. The stock trades above the $34.24 consensus target, suggesting limited near-term upside despite operational strength and dividend stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →
